DE-CSC
2.4.2020 08:02:12 CEST | Business Wire | Press release
CSC, the world’s leading provider of business, legal, tax, and digital brand services, is pleased to announce its completed acquisition of TCS-Groep (TCS), a Netherlands-based service provider for alternative investment funds (AIFs). The acquisition was first announced November 4, 2019, and was finalized with regulatory approval March 31, 2020.
The acquisition of TCS extends CSC’s capabilities for alternative investment managers and gives it a physical presence in another leading European financial center. CSC’s other European offices serving fund managers are in London, Luxembourg, and Dublin. The acquisition follows several strategic hires and investments CSC recently made, including the organic recruitment and set-up of its Fund Administration business in the U.S. and APAC markets.
“Beyond extending our capabilities in Europe, this acquisition reinforces our competitive advantage of being a privately held and independent service provider,” says CSC Senior Vice President John Hebert. “Our long-term stability and client-centric approach is highly valued by funds clients and makes for a strong cultural fit between our respective organizations. TCS has an impressive track record and similar service-oriented culture to our own. The combined offerings and shared reputation for high-quality client service create a unique offering in the marketplace every day, but even more so during these challenging times across the globe.”
Founded in 1991 and headquartered in Maarsbergen, Netherlands, TCS offers fund administration and depositary services for alternative asset managers with a focus on real estate, private equity, private debt, and social impact funds, and administers more than €6,8 billion in assets on behalf of its clients. TCS provides back office, compliance, accounting, tax, representation, and domiciliation services to funds based in the Netherlands, and is the largest non-banking depositary in the Netherlands.
“With the merger complete, together we’ll further accelerate our success in building the highest quality fund services business in the Netherlands and beyond. Working alongside the CSC team up until the moment of the merger has further strengthened my belief that CSC and TCS are the right match for this business,” says Birgitte van den Broek, CEO of TCS-Groep. “Our partnership reinforces the same commitment to service excellence that our clients have come to expect, but will now offer global diversity that will prove beneficial during these uncertain times. Our clients will continue to receive our personalized services from their existing client service teams, and both our clients and employees will benefit from the extended knowledge base now accessible via CSC.”
With this acquisition, Liam McHugh, managing director, will oversee CSC’s Fund Administration business in Europe. Rounding out CSC’s global fund administration footprint is Oleg Yablonovskiy, managing director in the U.S., and Agnes Chen, managing director in APAC. CSC has earned the trust of clients globally, and is the unwavering partner for over 60% of the top 100 global alternative asset managers.
“We’re excited to move forward as one team now that the acquisition is complete. The addition of TCS into our existing European business will provide further specialist expertise to our existing and new clients,” says Hebert.
TCS’s 26 staff across two offices will join CSC as part of the acquisition. Financial terms were not announced. Pepper Hamilton and Houthoff served as legal advisor to CSC. PhiDelphi Corporate Finance acted as sole financial advisor to TCS-Groep, and JanssenBroekhuysen provided legal advice.
About CSC
CSC is a leading provider of specialized administration services to alternative asset managers across a range of fund strategies, capital markets participants in both public and private markets, and corporations requiring fiduciary and governance support. We are the unwavering partner for 90% of the Fortune 500® , nearly 10,000 law firms, and more than 3,000 financial institutions. CSC’s Global Financial Markets professionals are located in key financial centers across the U.S., Europe, and Asia-Pacific. We are a global company capable of conducting transactions wherever our clients are―and we accomplish that by deploying experts in every business we serve. For more information about CSC’s services, visit cscgfm.com.
About TCS-Groep
TCS is a leading and reputable service provider in the Netherlands that offers fund-administrative and depositary services to asset managers of alternative investments. Services by TCS are characterized by long-term customer relationships, a stable workforce and first in class systems. While asset managers can concentrate on their core tasks, TCS assures smooth and compliant operations on the background. TCS takes great pride in being the largest non-banking depositary service provider in the Netherlands; as a depositary, TCS actively communicates with its clients so as to add real value to its operations, while securing proper fulfilment of all legal requirements. TCS holds licenses from the Dutch Central Bank (DNB) as well as from the Authority Financial Markets (AFM). For more information about TCS’s services, visit tcs-groep.nl.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200401005723/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
